Clover Health Investments (CLOV) Citi Annual Global Healthcare Conference 2025 summary

Business strategy and market focus

• Focuses on Medicare Advantage PPO plans, prioritizing member choice and quality of care in core markets of New Jersey and Georgia.

• Differentiates through proprietary AI-powered technology enabling earlier diagnosis and treatment of chronic diseases.

• Home care business unit led by MDs targets high-acuity patients, integrating technology for better outcomes.

• Growth is managed by targeting priority markets with strong physician and home care coverage.

• Over 90% of membership is concentrated in New Jersey, with significant runway for continued growth.

Technology and clinical outcomes

• Clover Assistant aggregates data from over 100 sources, providing actionable insights and AI-driven care recommendations.

• About two-thirds to 70% of members are managed under Clover Assistant, with rapid onboarding for new members.

• Clinical studies show earlier diagnosis of diabetes (by 3 years) and chronic kidney disease (by 1.5 years), leading to better outcomes and lower costs.

• Hospital admissions and readmissions are reduced by double-digit percentages, improving quality and lowering costs.

• AI scribing and proprietary ML models further reduce administrative burden and enhance physician efficiency.

Financial performance and profitability drivers

• Achieved 33-35% year-to-date membership growth and $45 million adjusted EBITDA, outperforming industry trends.

• Medical cost ratio improves by 700 basis points from year one to two, and another 700 from year two to three.

• Contribution profit per member per month is -$110 for new members and $217 for returning members, both expected to improve in 2026.

• SG&A as a percentage of revenue reduced by 370 basis points; cost trend normalized at 4% despite rapid growth.

• High voluntary member retention over 90% supports profitability as cohorts mature.